Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On February 24, 2026, FibroBiologics, Inc. (FBLG) announced financial results for 2025 and provided an operational update.</li><li>The company has secured both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial of CYWC628 for the treatment of diabetic foot ulcers (DFUs).</li><li>We anticipate the 120-patient study initiating in the first half of 2026 at up to 10 sites in Australia.</li></ul>

On February 24, 2026, FibroBiologics, Inc. (FBLG) announced financial results for 2025 and provided an operational update.The company has secured both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial of CYWC628 for the treatment of diabetic foot ulcers (DFUs).We anticipate the 120-patient study initiating in the first half of 2026 at up to 10 sites in Australia.

FBLG: Ready to Transition to Clinical-Stage Company